{"id":"NCT03737474","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder","officialTitle":"A Multi-center, Open-label Trial to Assess the Long-term Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-04","primaryCompletion":"2021-03-17","completion":"2021-04-13","firstPosted":"2018-11-09","resultsPosted":"2024-04-29","lastUpdate":"2024-04-29"},"enrollment":248,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Brexpiprazole","otherNames":[]}],"arms":[{"label":"Brexpiprazole","type":"EXPERIMENTAL"}],"summary":"This trial is a 52-week study to assess the safety of long-term use of brexpiprazole as adjunctive therapy in combination with an antidepressant.","primaryOutcome":{"measure":"The Frequency of Subjects With Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"From baseline to week 52","effectByArm":[{"arm":"New Subjects","deltaMin":96.8,"sd":null},{"arm":"Rollover Subjects","deltaMin":93.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["39424742"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":31},"commonTop":["Weight increased","Akathisia","Nasopharyngitis","Somnolence","Insomnia"]}}